Synergistic Effect of Lipoprotein-Associated Phospholipase A2 with Classical Risk Factors on Coronary Heart Disease: A Multi-Ethnic Study in China

Aims: We evaluated the synergistic effect of lipoprotein-associated phospholipase A2 (Lp-PLA2) in association with classical risk factors in predicting coronary heart disease (CHD) and demonstrated the diagnostic value of Lp-PLA2 for predicting coronary stenotic lesions in subjects with CHD. Methods: Blood samples were acquired from 911 consecutive adult subjects (662 males and 249 females) from 11 ethnic groups. Lp-PLA2 plasma levels were detected using a commercially available turbidimetric immunoassay (TIA). CHD in patients was confirmed using coronary angiography, and the severity of coronary atherosclerosis was assessed using the Gensini scoring system. Results: A binary logistic regression was performed to analyse the relationships between Lp-PLA2 and other risk factors. A multivariate logistic regression analysis revealed that Lp-PLA2 levels were significantly associated with CHD (OR, 1.882; 95% CI, 1.369-2.587, p=0.000).The area under the receiver operating characteristic curve for Lp-PLA2 was 0.589 (95%CI, 0.549-0.629, p=0.000).The synergism between Lp-PLA2 and other risk factors was also investigated. The proportion of CHD attributable to the interaction between Lp-PLA2 and age was as high as 64%. Conclusions: Lp-PLA2 levels in human plasma were positively associated with the severity of CHD, and there was a clear positive interaction between Lp-PLA2 and classical risk factors in predicting CHD.

• Publication year

  2016

• Venue

  Cellular Physiology and Biochemistry

• Publication date

  2016-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000453153PMID 27941334
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Correlation between the High Density Lipoprotein and its Subtypes in Coronary Heart Disease

  2016cited by this paper
• Of markets and rights: Discourse in the 2008 and 2013 Global Action Plan for the Prevention and Control of Noncommunicable Diseases

  2016cited by this paper
• Lipoprotein‐Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease

  2016cited by this paper
• Atherosclerosis-Associated Endothelial Cell Apoptosis by MiR-429-Mediated Down Regulation of Bcl-2

  2015cited by this paper
• Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.

  2015cited by this paper
• Coronary heart disease and genetic variants with low phospholipase A2 activity.

  2015cited by this paper
• The association between uncarboxylated matrix Gla protein and lipoprotein-associated phospholipase A2.

  2015cited by this paper
• Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players.

  2014cited by this paper
• Darapladib for preventing ischemic events in stable coronary heart disease.

  2014cited by this paper
• [Influence of intensive hypolipidemic therapy on blood concentration of lipoprotein-associated phospholipase A2 in patients with ischemic heart disease].

  2013cited by this paper
• Changes in Lipoprotein‐Associated Phospholipase A2 Activity Predict Coronary Events and Partly Account for the Treatment Effect of Pravastatin: Results From the Long‐term Intervention with Pravastatin in Ischemic Disease Study

  2013cited by this paper
• Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies.

  2012cited by this paper
• Relationship between brachial-ankle pulse wave velocity and cardiovascular risk factors: a multi-ethnic study.

  2012cited by this paper
• Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature.

  2012cited by this paper
• Circulating microRNA-126 in patients with coronary artery disease: correlation with LDL cholesterol

  2012cited by this paper
• Elevated plasma lipoprotein-associated phospholipase A₂ activity is associated with plaque rupture in patients with coronary artery disease.

  2011cited by this paper
• Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome.

  2011cited by this paper
• Sequencing of Lp-PLA2-encoding PLA2G7 gene in 2000 Europeans reveals several rare loss-of-function mutations

  2011cited by this paper
• PLA2G7 Genotype, Lipoprotein-Associated Phospholipase A2 Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624 Controls of European Ancestry

  2010cited by this paper
• Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature.

  2010cited by this paper
• Rates and Determinants of Coronary and Abdominal Aortic Artery Calcium Progression in the Veterans Affairs Diabetes Trial (VADT)

  2010cited by this paper
• Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

  2010cited by this paper
• Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study.

  2010cited by this paper
• Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study.

  2009cited by this paper
• SMOKING AND CORONARY ATHEROSCLEROSIS: FOLLOW‐UP STUDY IN CHINA

  2009cited by this paper
• High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 Stability Before and After Stroke and Myocardial Infarction

  2009cited by this paper
• Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

  2008cited by this paper
• Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study.

  2008cited by this paper
• Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients.

  2007cited by this paper
• Lipoprotein-Associated Phospholipase A2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis

  2006cited by this paper
• Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death.

  2006cited by this paper
• Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects.

  2005cited by this paper
• Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study

  2005cited by this paper
• The effect of statin therapy on lipoprotein associated phospholipase A2 levels.

  2005cited by this paper
• Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.

  2005cited by this paper
• Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity With Calcified Coronary Plaque in Young Adults: The CARDIA Study

  2004cited by this paper
• Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus.

  2004cited by this paper
• Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study

  2004cited by this paper
• Leukocyte count and coronary heart disease: implications for risk assessment.

  2004cited by this paper
• Associations of body mass index and obesity with physical activity, food choices, alcohol intake, and smoking in the 1982-1997 FINRISK Studies.

  2002cited by this paper
• HDLassociated PAF‐AH reduces endothelial adhesiveness in apoE−/− mice

  2000cited by this paper
• Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease.

  2000cited by this paper
• Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease

  2000cited by this paper
• Atherosclerosis--an inflammatory disease.

  1999cited by this paper
• Atherosclerosis--an inflammatory disease.

  1999cited by this paper
• Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor.

  1999cited by this paper
• Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.

  1998cited by this paper
• Evolving methods in genetic epidemiology. III. Gene-environment interaction in epidemiologic research.

  1997cited by this paper
• Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins.

  1997cited by this paper
• Confidence Intervals for Measures of Interaction

  1996cited by this paper
• A more meaningful scoring system for determining the severity of coronary heart disease.

  1983cited by this paper
• The meaning and use of the area under a receiver operating characteristic (ROC) curve.

  1982cited by this paper
• Selective coronary arteriography. I. A percutaneous transfemoral technic.

  1967cited by this paper
• Selective Coronary Arteriography

  1967cited by this paper

• Emerging Circulating Biomarkers for Enhanced Cardiovascular Risk Prediction

  2024cites this paper
• Enhancement of Bottle Gourd Oil Activity via Optimized Self-Dispersing Lipid Formulations (SDLFs) to Mitigate Isoproterenol-Evoked Cardiac Toxicity in Rats via Modulating BMP, MMP2, and miRNA-21 and miRNA-23a Genes’ Expression

  2023cites this paper
• miR194 hypomethylation regulates coronary artery disease pathogenesis

  2022cites this paper
• A Systematic Review of Body Fluids Biomarkers Associated With Early Neurological Deterioration Following Acute Ischemic Stroke

  2022cites this paper
• Panax notoginseng Saponins Alleviate Coronary Artery Disease Through Hypermethylation of the miR-194-MAPK Pathway

  2022influential citation
• Elevated Lipoprotein-Associated Phospholipase A2 Independently Affects Age-Related Increases in Systolic Blood Pressure: A Nested Case-Control Study in a Prospective Korean Cohort

  2020cites this paper
• Phospholipase A2 is an Inflammatory Predictor in Cardiovascular Diseases: Is there any Spacious Room to Prove the Causation?

  2020cites this paper
• [Role of markers of inflammation and endothelial dysfunction in the prognosis of the development of cardiovascular complications in patients with coronary artery disease and metabolic syndrome after coronary stenting].

  2020cites this paper
• Associations between single nucleotide polymorphisms in miR-221, self-reported essential hypertension, and interactions between genetic and environmental factors: a multiethnic study in China.

  2019cites this paper
• Markers of Atherosclerosis: Part 2 - Genetic and Imaging Markers.

  2019cites this paper
• Markers of Atherosclerosis: Part 1 - Serological Markers.

  2019cites this paper
• Performance Characteristics and Clinical Value of the Lipoprotein-Associated Phospholipase A2 by an Enzymatic Kinetic Method.

  2019cites this paper
• Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study

  2019cites this paper
• DNA methylation of antisense noncoding RNA in the INK locus (ANRIL) is associated with coronary artery disease in a Chinese population

  2019cites this paper
• Lipoprotein-Associated Phospholipase A 2 Activity Level may be complementary to Cardiactroponin I as a Biomarker for Acute Myocardial Infarction in Chinese Patients with Chest Pain

  2018cites this paper
• EBF1 gene polymorphism and its interaction with smoking and drinking on the risk of coronary artery disease for Chinese patients

  2018cites this paper
• Review of biomarkers to assess the effects of switching from cigarettes to modified risk tobacco products

  2018cites this paper
• Характеристика клеточного звена врождённого иммунитета у пациентов, перенесших коронарное стентирование

  2018cites this paper
• Single-nucleotide polymorphism rs731384 is associated with plasma lipid levels and the risk of coronary artery disease in Chinese populations

  2018cites this paper
• Lp-PLA2 as a risk factor of early neurological deterioration in acute ischemic stroke with TOAST type of large arterial atherosclerosis

  2018cites this paper
• Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China

  2017cites this paper